Antitumor activity of Virulizin, a novel biological response modifier (BRM) in a panel of human pancreatic cancer and melanoma xenografts

To define the anticancer efficacy of Virulizin in vivo as a single agent or in combination with conventional drugs in human pancreatic tumor and melanoma xenografts. The therapeutic effect of Virulizin was evaluated in a series of human tumor xenografts in athymic nude mice. Virulizin had a high lev...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer chemotherapy and pharmacology 2003-03, Vol.51 (3), p.247-255
Hauptverfasser:	NINGPING FENG, HONGNAN JIN, MING WANG, CAIGAN DU, WRIGHT, Jim A, YOUNG, Aiping H
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants, Immunologic - administration & dosage Adjuvants, Immunologic - pharmacology Animals Antineoplastic agents Bile Biological and medical sciences Chemotherapy Female Humans Injections, Intramuscular Injections, Intraperitoneal Medical sciences Melanoma - drug therapy Melanoma - veterinary Mice Mice, Nude Neoplasms, Experimental Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - veterinary Pharmacology. Drug treatments Skin Neoplasms - drug therapy Skin Neoplasms - veterinary Tissue Extracts Transplantation, Heterologous
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	To define the anticancer efficacy of Virulizin in vivo as a single agent or in combination with conventional drugs in human pancreatic tumor and melanoma xenografts. The therapeutic effect of Virulizin was evaluated in a series of human tumor xenografts in athymic nude mice. Virulizin had a high level of antitumor activity against all the pancreatic tumors (BxPC-3, SU 86.86. and Mia-PaCa-2) and melanomas (C8161 and A2058), as indicated by suppression of tumor growth with an optimal T/C value of
ISSN:	0344-5704 1432-0843
DOI:	10.1007/s00280-002-0559-7